SCPHARMACEUTICALS INC (SCPH) Stock Price, Forecast & Analysis
USA - NASDAQ:SCPH - US8106481059 - Common Stock
SCPH Key Statistics, Chart & Performance
The current stock price of SCPH is 5.67 USD. In the past month the price increased by 1.7%. In the past year, price increased by 34.04%.
SCPH Latest News, Press Relases and Analysis
SCPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.2 | 940.69B | ||
| JNJ | JOHNSON & JOHNSON | 18.53 | 463.20B | ||
| MRK | MERCK & CO. INC. | 10.25 | 225.65B | ||
| PFE | PFIZER INC | 7.86 | 143.05B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.33 | 97.89B | ||
| ZTS | ZOETIS INC | 19.03 | 53.47B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.5 | 22.77B | ||
| VTRS | VIATRIS INC | 4.66 | 12.67B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.91 | 11.40B | ||
| CORT | CORCEPT THERAPEUTICS INC | 89.57 | 8.31B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.02B | ||
| LGND | LIGAND PHARMACEUTICALS | 29.11 | 4.16B |
Related stock screener links
About SCPH
Company Profile
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The company is headquartered in Burlington, Massachusetts and currently employs 162 full-time employees. The company went IPO on 2017-11-17. The firm is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company’s strategy is to develop therapies for subcutaneous administration that have previously been limited to intravenous (IV) delivery. Its commercial product, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Company’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Company Info
SCPHARMACEUTICALS INC
25 Mall Road, Suite 203
Burlington MASSACHUSETTS 01803 US
CEO: John H. Tucker
Employees: 163
Phone: 16175170730
SCPHARMACEUTICALS INC / SCPH FAQ
What does SCPHARMACEUTICALS INC do?
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The company is headquartered in Burlington, Massachusetts and currently employs 162 full-time employees. The company went IPO on 2017-11-17. The firm is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company’s strategy is to develop therapies for subcutaneous administration that have previously been limited to intravenous (IV) delivery. Its commercial product, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Company’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
What is the current price of SCPH stock?
The current stock price of SCPH is 5.67 USD.
What is the dividend status of SCPHARMACEUTICALS INC?
SCPH does not pay a dividend.
What is the ChartMill technical and fundamental rating of SCPH stock?
SCPH has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists SCPH stock?
SCPH stock is listed on the Nasdaq exchange.
What is SCPHARMACEUTICALS INC worth?
SCPHARMACEUTICALS INC (SCPH) has a market capitalization of 304.37M USD. This makes SCPH a Small Cap stock.
What is the ownership structure of SCPHARMACEUTICALS INC (SCPH)?
You can find the ownership structure of SCPHARMACEUTICALS INC (SCPH) on the Ownership tab.
SCPH Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to SCPH. When comparing the yearly performance of all stocks, SCPH is one of the better performing stocks in the market, outperforming 88.16% of all stocks.
SCPH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SCPH. Both the profitability and financial health of SCPH have multiple concerns.
SCPH Financial Highlights
Over the last trailing twelve months SCPH reported a non-GAAP Earnings per Share(EPS) of -1.81. The EPS decreased by -16.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -114.28% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SCPH Forecast & Estimates
10 analysts have analysed SCPH and the average price target is 12.33 USD. This implies a price increase of 117.45% is expected in the next year compared to the current price of 5.67.
For the next year, analysts expect an EPS growth of 41.66% and a revenue growth 100.79% for SCPH